Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation
JAMA · 07.04.2026 · 335 (13) · 1127
DOI: 10.1001/jama.2026.0076 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 07.04.2026. Verfasst von Ayal A Aizer und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Brain Neoplasms, Cranial Irradiation, Hippocampus, Organ Sparing Treatments. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Brain metastases are common in patients with cancer, and radiation is often used for management. Among patients with more than 4 brain metastases, the effects of stereotactic radiation targeting only individual tumors, compared with whole brain radiation with hippocampal avoidance, which radiates both tumors and normal brain, remain unknown.
Objective
To determine whether stereotactic radiation improves symptom severity and interference with daily functioning, compared with whole brain radiation with hippocampal avoidance. Design, Setting, and Participants Phase 3, open-label, randomized clinical trial conducted at 4 United States–based centers. Eligible patients had 5 to 20 brain metastases and no prior brain-directed radiation. Enrollment occurred between April 11, 2017, and May 17, 2024 (final follow-up, March 18, 2025).
Intervention
Stereotactic radiation, compared with whole brain radiation with hippocampal avoidance. Main Outcomes and Measures Mean weighted patient-reported symptom severity and interference score change over 6 months postbaseline relative to baseline using the MD Anderson Symptom Inventory–Brain Tumor instrument (scale, 0-10; score change range, −10 to 10; −10 = best). A clinically meaningful Δ was defined as 0.98.
Results
Of 196 randomized patients (mean age, 61 years; 129 [66%] female; 176 [90%] White; median number of brain metastases, 14 [IQR, 11-18]; 49 [25%] with prior neurosurgical resection), 83 (42%) completed the 6-month assessment. For the primary outcome, between baseline and postbaseline assessments through the 6-month follow-up, stereotactic radiation changed the weighted composite MD Anderson Symptom Inventory–Brain Tumor score from 2.69 to 2.37 (mean change, −0.32) and hippocampal-avoidance whole brain radiation changed the score from 2.29 to 3.03 (mean change, 0.74) (mean difference, −1.06 [95% CI, −1.54 to −0.58]; P < .001). Related grade 3-5 adverse events occurred in 12 patients (12%) in the stereotactic radiation group and 13 patients (13%) in the hippocampal-avoidance whole brain radiation group; grade 1-3 fatigue was most frequent (27 [28%] vs 43 [44%], respectively). Conclusions and Relevance In patients with 5 to 20 brain metastases, these findings support stereotactic radiation over hippocampal-avoidance whole brain radiation to improve symptoms and interference with daily functioning, key components of quality of life. Trial Registration ClinicalTrials.gov Identifier: NCT03075072
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
- Department of Radiation Oncology, Milford Regional Medical Center, Milford, Massachusetts.
- Department of Radiation Oncology, South Shore Health, Weymouth, Massachusetts.
- Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Aizer, A. A., Shin, K. Y., Catalano, P. J., Ricca, I., Johnson, M., Benham, G., Roper, K., Spicer, B., Mann, E., Nosker, J., Parsons, M. W., Mendu, M. L., Hepel, J., Chipidza, F., Krishnan, M., Shi, D. D., Lamba, N., Pashtan, I., Peng, L., …, & Tanguturi, S. (2026). Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation. JAMA, 335(13), 1127. https://doi.org/10.1001/jama.2026.0076
Vancouver
Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, et al. Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation. JAMA. 2026;335(13):1127. doi:10.1001/jama.2026.0076
BibTeX
@article{Aizer2026,
author = {Aizer, Ayal A and Shin, Kee-Young and Catalano, Paul J and Ricca, Ivy and Johnson, Marciana and Benham, Grant and Roper, Kristin and Spicer, Beverly and Mann, Eileen and Nosker, Jennifer and Parsons, Michael W and Mendu, Mallika L and Hepel, Jaroslaw and Chipidza, Fallon and Krishnan, Monica and Shi, Diana D and Lamba, Nayan and Pashtan, Itai and Peng, Luke and Alexander, Brian and Brown, Paul D and Wen, Patrick Y and Haas-Kogan, Daphne A and Rahman, Rifaquat and Tanguturi, Shyam},
title = {Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation},
journal = {JAMA},
year = {2026},
volume = {335},
number = {13},
pages = {1127},
doi = {10.1001/jama.2026.0076}
}
EUVIMED